Kadmon (KDMN) Receives “Positive” Rating from Piper Jaffray Companies

Kadmon (NYSE:KDMN)‘s stock had its “positive” rating restated by investment analysts at Piper Jaffray Companies in a research report issued to clients and investors on Tuesday. They presently have a $9.00 price objective on the stock, up from their prior price objective of $7.00. Piper Jaffray Companies’ price target would indicate a potential upside of 137.47% from the stock’s current price.

Several other equities research analysts have also recently commented on the stock. Jefferies Group boosted their price target on shares of Kadmon to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered shares of Kadmon from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Kadmon in a research note on Friday, December 15th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Kadmon currently has a consensus rating of “Hold” and an average target price of $10.21.

Shares of Kadmon (NYSE:KDMN) opened at $3.79 on Tuesday. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86.

Several institutional investors have recently added to or reduced their stakes in KDMN. Goldentree Asset Management LP increased its stake in shares of Kadmon by 673.6% during the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock worth $5,834,000 after purchasing an additional 1,403,397 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in shares of Kadmon during the 3rd quarter worth about $3,685,000. Vanguard Group Inc. increased its stake in shares of Kadmon by 166.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after purchasing an additional 941,549 shares during the last quarter. Crestline Management LP acquired a new position in shares of Kadmon during the 3rd quarter worth about $2,011,000. Finally, Sabby Management LLC acquired a new position in shares of Kadmon during the 2nd quarter worth about $2,112,000. Institutional investors own 51.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/02/15/kadmon-kdmn-receives-positive-rating-from-piper-jaffray-companies.html.

Kadmon Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Analyst Recommendations for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply